The association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors

Abstract Background Intracranial solitary fibrous tumor (SFT) is a rare mesenchymal tumor of fibroblastic origin in the central nervous system (CNS). The 2021 WHO classification of CNS tumor has updated the entity and grading criterion of SFT. We aimed to compare the 2021 WHO grading criterion (2021...

Full description

Saved in:
Bibliographic Details
Main Authors: Leihao Ren, Lingyang Hua, AO Feng, Jiaojiao Deng, Hiroaki Wakimoto, Tareq Juratli, Qing Xie, Ye Gong
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Acta Neuropathologica Communications
Subjects:
Online Access:https://doi.org/10.1186/s40478-025-02086-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849738819009511424
author Leihao Ren
Lingyang Hua
AO Feng
Jiaojiao Deng
Hiroaki Wakimoto
Tareq Juratli
Qing Xie
Ye Gong
author_facet Leihao Ren
Lingyang Hua
AO Feng
Jiaojiao Deng
Hiroaki Wakimoto
Tareq Juratli
Qing Xie
Ye Gong
author_sort Leihao Ren
collection DOAJ
description Abstract Background Intracranial solitary fibrous tumor (SFT) is a rare mesenchymal tumor of fibroblastic origin in the central nervous system (CNS). The 2021 WHO classification of CNS tumor has updated the entity and grading criterion of SFT. We aimed to compare the 2021 WHO grading criterion (2021-WGC) and 2016 WHO grading criterion (2016-WGC) for their value to predict prognosis and radiotherapy (RT) efficacy. Methods This is a retrospective study involving 223 consecutive intracranial SFT patients who received tumor resection at our neurosurgical center from 2013 to 2021. Univariable and multivariable Cox regression analyses were utilized to identify prognosis-related factors and evaluate the efficacy of RT. A risk model was constructed to predict the long-term recurrence. Results A total of 223 SFT patients were included in this study. During a median follow-up period of 4.67 years, 80 (35.9%) patients experienced tumor recurrence and 14 (6.3%) experienced extracranial metastasis. Patients with SFT who developed recurrence were significantly older at diagnosis and exhibited higher Ki-67 index and mitotic count. Of note, the PFS of 2016-WGC grade 3 tumors was worse than the comparable PFS of grade 1 and 2 tumors (P = 0.001), while the PFS of 2021-WGC grade 1 tumors was better than grade 2 and 3 tumors that showed similar PFS in the long term (P < 0.001). We further proposed a novel risk stratification method that demonstrated a superior prognostic value compared to the 2021-WGC and 2016-WGC. Additionally, RT significantly prolonged the PFS of SFT patients, especially beyond 3 years after surgery (P = 0.032). Further efficacy analysis showed that RT prolonged PFS in the 2016-grade 3 tumors. While with the 2021-WGC and novel risk stratification, RT prolonged PFS in the 2021-grade 2 and intermediate risk tumors, respectively. Conclusions The 2016-WGC identified high-recurrence risk patients in grade 3 while the 2021-WGC identified low-recurrence risk patients in grade 1. RT significantly prolonged PFS in SFT patients, especially after 3 years post-surgery. Notably, RT significantly improved PFS in the 2016-grade 3, 2021-grade 2 and intermediate risk tumors.
format Article
id doaj-art-5c8b31e1bd834f97ade22e4dfcc911c7
institution DOAJ
issn 2051-5960
language English
publishDate 2025-08-01
publisher BMC
record_format Article
series Acta Neuropathologica Communications
spelling doaj-art-5c8b31e1bd834f97ade22e4dfcc911c72025-08-20T03:06:27ZengBMCActa Neuropathologica Communications2051-59602025-08-0113111110.1186/s40478-025-02086-wThe association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumorsLeihao Ren0Lingyang Hua1AO Feng2Jiaojiao Deng3Hiroaki Wakimoto4Tareq Juratli5Qing Xie6Ye Gong7Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan UniversityDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan UniversityDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan UniversityDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan UniversityDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical SchoolDepartment of Neurosurgery, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität DresdenDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan UniversityDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan UniversityAbstract Background Intracranial solitary fibrous tumor (SFT) is a rare mesenchymal tumor of fibroblastic origin in the central nervous system (CNS). The 2021 WHO classification of CNS tumor has updated the entity and grading criterion of SFT. We aimed to compare the 2021 WHO grading criterion (2021-WGC) and 2016 WHO grading criterion (2016-WGC) for their value to predict prognosis and radiotherapy (RT) efficacy. Methods This is a retrospective study involving 223 consecutive intracranial SFT patients who received tumor resection at our neurosurgical center from 2013 to 2021. Univariable and multivariable Cox regression analyses were utilized to identify prognosis-related factors and evaluate the efficacy of RT. A risk model was constructed to predict the long-term recurrence. Results A total of 223 SFT patients were included in this study. During a median follow-up period of 4.67 years, 80 (35.9%) patients experienced tumor recurrence and 14 (6.3%) experienced extracranial metastasis. Patients with SFT who developed recurrence were significantly older at diagnosis and exhibited higher Ki-67 index and mitotic count. Of note, the PFS of 2016-WGC grade 3 tumors was worse than the comparable PFS of grade 1 and 2 tumors (P = 0.001), while the PFS of 2021-WGC grade 1 tumors was better than grade 2 and 3 tumors that showed similar PFS in the long term (P < 0.001). We further proposed a novel risk stratification method that demonstrated a superior prognostic value compared to the 2021-WGC and 2016-WGC. Additionally, RT significantly prolonged the PFS of SFT patients, especially beyond 3 years after surgery (P = 0.032). Further efficacy analysis showed that RT prolonged PFS in the 2016-grade 3 tumors. While with the 2021-WGC and novel risk stratification, RT prolonged PFS in the 2021-grade 2 and intermediate risk tumors, respectively. Conclusions The 2016-WGC identified high-recurrence risk patients in grade 3 while the 2021-WGC identified low-recurrence risk patients in grade 1. RT significantly prolonged PFS in SFT patients, especially after 3 years post-surgery. Notably, RT significantly improved PFS in the 2016-grade 3, 2021-grade 2 and intermediate risk tumors.https://doi.org/10.1186/s40478-025-02086-wIntracranial solitary fibrous tumorProgression-free survivalWHO gradeRadiotherapy
spellingShingle Leihao Ren
Lingyang Hua
AO Feng
Jiaojiao Deng
Hiroaki Wakimoto
Tareq Juratli
Qing Xie
Ye Gong
The association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors
Acta Neuropathologica Communications
Intracranial solitary fibrous tumor
Progression-free survival
WHO grade
Radiotherapy
title The association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors
title_full The association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors
title_fullStr The association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors
title_full_unstemmed The association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors
title_short The association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors
title_sort association between who grading and the long term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors
topic Intracranial solitary fibrous tumor
Progression-free survival
WHO grade
Radiotherapy
url https://doi.org/10.1186/s40478-025-02086-w
work_keys_str_mv AT leihaoren theassociationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT lingyanghua theassociationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT aofeng theassociationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT jiaojiaodeng theassociationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT hiroakiwakimoto theassociationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT tareqjuratli theassociationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT qingxie theassociationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT yegong theassociationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT leihaoren associationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT lingyanghua associationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT aofeng associationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT jiaojiaodeng associationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT hiroakiwakimoto associationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT tareqjuratli associationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT qingxie associationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors
AT yegong associationbetweenwhogradingandthelongtermoutcomesandradiotherapyefficacyofintracranialsolitaryfibroustumors